Published in Clin Exp Immunol on May 01, 2000
Interplay of host microbiota, genetic perturbations, and inflammation promotes local development of intestinal neoplasms in mice. J Exp Med (2014) 1.76
Genetic polymorphisms of matrix metalloproteinase 3 in primary sclerosing cholangitis. Liver Int (2010) 1.54
Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut (2006) 1.47
Immunoregulation in the gut: success and failures in human disease. Gut (2002) 1.25
Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease. Gut (2004) 1.21
Colonic subepithelial myofibroblasts in mucosal inflammation and repair: contribution of bone marrow-derived stem cells to the gut regenerative response. J Gastroenterol (2005) 1.12
TACE activation by MAPK-mediated regulation of cell surface dimerization and TIMP3 association. Sci Signal (2012) 1.11
High levels of proinflammatory cytokines, but not markers of tissue injury, in unaffected intestinal areas from patients with IBD. Mediators Inflamm (2009) 1.09
Cellular and molecular mechanisms of intestinal fibrosis. World J Gastroenterol (2012) 1.07
Plasma matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 as biomarkers of ulcerative colitis activity. World J Gastroenterol (2003) 1.02
Effect of infliximab on small bowel stenoses in patients with Crohn's disease. World J Gastroenterol (2008) 0.94
The distinct roles of MMP-2 and MMP-9 in acute DSS colitis. Eur J Microbiol Immunol (Bp) (2011) 0.93
Protein kinase D1 mediates synergistic MMP-3 expression induced by TNF-α and bradykinin in human colonic myofibroblasts. Biochem Biophys Res Commun (2011) 0.92
Matrix metalloproteinase-9: its interplay with angiogenic factors in inflammatory bowel diseases. Dis Markers (2014) 0.89
Collagen in colon disease. Hernia (2006) 0.89
Expression of matrix metalloproteinases and tissue inhibitor metalloproteinases increases in X-irradiated rat ileum despite the disappearance of CD8a T cells. World J Gastroenterol (2005) 0.86
Selective gelatinase blockage ameliorates acute DSS colitis. Eur J Microbiol Immunol (Bp) (2011) 0.86
Spontaneous and cytokine induced expression and activity of matrix metalloproteinases in human colonic epithelium. Clin Exp Immunol (2009) 0.86
Interleukin-1beta-induced promatrilysin expression is mediated by NFkappaB-regulated synthesis of interleukin-6 in the prostate carcinoma cell line, LNCaP. Neoplasia (2002) 0.85
Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases. World J Gastroenterol (2012) 0.85
Increased protein expression of matrix metalloproteinases -1, -3, and -9 and TIMP-1 in patients with gluten-sensitive enteropathy. Dig Dis Sci (2006) 0.84
Correlation of MMP-3 and MMP-9 with Crohn's disease activity in children. Dig Dis Sci (2011) 0.83
Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis. Mucosal Immunol (2014) 0.81
Inhibitory effects of short-chain fatty acids on matrix metalloproteinase secretion from human colonic subepithelial myofibroblasts. Dig Dis Sci (2008) 0.81
Validated gene expression biomarker analysis for biopsy-based clinical trials in ulcerative colitis. Aliment Pharmacol Ther (2014) 0.79
Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease. World J Gastroenterol (2015) 0.79
Imbalance of tissue inhibitors of metalloproteinases (TIMP) - 1 and - 4 serum levels, in patients with inflammatory bowel disease. BMC Gastroenterol (2008) 0.78
Regulation of intestinal permeability: The role of proteases. World J Gastroenterol (2017) 0.75
Novel Biomarkers and the Future Potential of Biomarkers in Inflammatory Bowel Disease. Mediators Inflamm (2017) 0.75
The synthetic hydroxyproline-containing collagen analogue (Gly-Pro-Hyp)10 ameliorates acute DSS colitis. Eur J Microbiol Immunol (Bp) (2012) 0.75
Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol (1993) 4.68
Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology (1979) 3.94
Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci (1992) 2.47
Microscopic activity in ulcerative colitis: what does it mean? Gut (1991) 2.43
Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev (1990) 2.42
Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology (1995) 2.38
A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol (1997) 2.13
TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages. J Immunol (1996) 1.96
Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology (1999) 1.88
Biosynthesis of tissue inhibitor of metalloproteinases by human fibroblasts in culture. Stimulation by 12-O-tetradecanoylphorbol 13-acetate and interleukin 1 in parallel with collagenase. J Biol Chem (1985) 1.86
Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption. Endocrinology (1998) 1.75
Enhanced expression of matrilysin, collagenase, and stromelysin-1 in gastrointestinal ulcers. Am J Pathol (1996) 1.72
Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology (1997) 1.69
IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest (1995) 1.69
Distribution of the matrix metalloproteinases stromelysin, gelatinases A and B, and collagenase in Crohn's disease and normal intestine. J Clin Pathol (1994) 1.60
Interleukin-6 induces the synthesis of tissue inhibitor of metalloproteinases-1/erythroid potentiating activity (TIMP-1/EPA). J Biol Chem (1991) 1.58
A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production. J Immunol (1998) 1.53
Regulation of the autoactivation of human 72-kDa progelatinase by tissue inhibitor of metalloproteinases-2. J Biol Chem (1991) 1.40
Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease (IBD). Clin Exp Immunol (1995) 1.30
In situ expression of interleukin-10 in noninflamed human gut and in inflammatory bowel disease. Am J Pathol (1998) 1.28
Interleukin-10 modulates type I collagen and matrix metalloprotease gene expression in cultured human skin fibroblasts. J Clin Invest (1994) 1.28
Suppression of T cell-mediated injury in human gut by interleukin 10: role of matrix metalloproteinases. Gastroenterology (1998) 1.14
Effects of interleukin-6 on the metabolism of connective tissue components in rheumatoid synovial fibroblasts. Arthritis Rheum (1992) 1.13
Involvement of interleukin-4 and -10 in inflammatory bowel disease. Dig Dis Sci (1996) 1.01
Human alveolar macrophages secrete an inhibitor of metalloproteinase elastase. Am Rev Respir Dis (1987) 0.92
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature (2001) 33.12
Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut (2001) 4.23
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis (2004) 3.64
Metabolic and respiratory changes after cholecystectomy performed via laparotomy or laparoscopy. Br J Anaesth (1992) 3.50
Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg (1992) 2.96
Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guérin vaccination. J Immunol (1999) 2.94
Long-term observations of vertebral osteoporotic fractures treated by percutaneous vertebroplasty. Rheumatology (Oxford) (2000) 2.76
Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab? Aliment Pharmacol Ther (2012) 2.74
Office gel sonovaginography for the prediction of posterior deep infiltrating endometriosis: a multicenter prospective observational study. Ultrasound Obstet Gynecol (2014) 2.67
Genetic analyses of chromosome 12 loci in Crohn's disease. Gut (2000) 2.30
Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol (1998) 2.20
Spurious counts and spurious results on haematology analysers: a review. Part II: white blood cells, red blood cells, haemoglobin, red cell indices and reticulocytes. Int J Lab Hematol (2007) 2.16
A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study. Rheumatology (Oxford) (2005) 2.05
Interleukin-10 production during septicaemia. Lancet (1994) 2.05
Predicting relapse in Crohn's disease: a biopsychosocial model. Gut (2008) 2.01
Use of Sysmex XE-2100 and XE-5000 hematology analyzers for the diagnosis of malaria in a nonendemic country (France). Int J Lab Hematol (2013) 1.99
Spurious counts and spurious results on haematology analysers: a review. Part I: platelets. Int J Lab Hematol (2007) 1.92
Interleukin-10 controls interferon-gamma and tumor necrosis factor production during experimental endotoxemia. Eur J Immunol (1994) 1.92
Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther (2004) 1.87
A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn's disease. Eur J Gastroenterol Hepatol (1997) 1.85
Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment Pharmacol Ther (2004) 1.62
Association between myelodysplastic syndromes and inflammatory bowel diseases. Report of seven new cases and review of the literature. Leukemia (1997) 1.50
The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases. Genes Immun (2007) 1.50
Clinical and ultrasonographic predictors of joint replacement for knee osteoarthritis: results from a large, 3-year, prospective EULAR study. Ann Rheum Dis (2009) 1.47
EULAR report on the use of ultrasonography in painful knee osteoarthritis. Part 1: prevalence of inflammation in osteoarthritis. Ann Rheum Dis (2005) 1.44
Androgen excess in women with acne alone compared with women with acne and/or hirsutism. J Invest Dermatol (1990) 1.44
Epidermal interleukin-8 and its receptor CXCR2 in drug-induced toxic epidermal necrolysis. Clin Exp Dermatol (2007) 1.41
Effective treatment of Jo-1-associated polymyositis with T-cell-depleted autologous peripheral blood stem cell transplantation. Br J Haematol (2000) 1.41
Misdiagnosed malignancy in transplanted organs. Transpl Int (1993) 1.40
[Acute tubulo-interstitial nephropathy with uveitis: apropos of case]. Acta Clin Belg (1996) 1.39
A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol (2002) 1.38
Establishment, characterization and virus expression of cell lines derived from radiation- and virus-induced lymphomas of C57BL/Ka mice. Int J Cancer (1979) 1.35
Human dendritic cell responses to lipopolysaccharide and CD40 ligation are differentially regulated by interleukin-10. Eur J Immunol (1997) 1.27
Tumor necrosis factor alpha decreases, and interleukin-10 increases, the sensitivity of human monocytes to dexamethasone: potential regulation of the glucocorticoid receptor. J Clin Endocrinol Metab (1999) 1.25
A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs. Ann Rheum Dis (2006) 1.24
Interleukin-10 prevents the generation of dendritic cells from human peripheral blood mononuclear cells cultured with interleukin-4 and granulocyte/macrophage-colony-stimulating factor. Eur J Immunol (1997) 1.24
High levels of sTNFR p75 and TNF alpha in dengue-infected patients. Microbiol Immunol (1996) 1.19
Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis. J Crohns Colitis (2011) 1.18
Factors that influence cancer patients' anxiety following a medical consultation: impact of a communication skills training programme for physicians. Ann Oncol (2006) 1.16
Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol (1999) 1.15
Isolation of follicular dendritic cells from human tonsils and adenoids. II. Immunocytochemical characterization. Eur J Immunol (1984) 1.12
High levels of p105 (NFKB1) and p100 (NFKB2) proteins in HPV16-transformed keratinocytes: role of E6 and E7 oncoproteins. Virology (2005) 1.10
Assessment of Ki-67 antigen immunostaining in squamous intraepithelial lesions of the uterine cervix. Correlation with the histologic grade and human papillomavirus type. Am J Clin Pathol (1995) 1.07
Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood: II. Application to rheumatoid arthritis and osteoarthritis. Cytokine (1992) 1.06
WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis. Rheumatology (Oxford) (2001) 1.06
Tumour necrosis factor (TNF) gene polymorphism in Crohn's disease (CD): influence on disease behaviour? Clin Exp Immunol (2000) 1.06
Production of tumour necrosis factor-alpha, interferon-gamma and interleukin-2 by peripheral blood mononuclear cells of subjects suffering from rheumatoid arthritis. Scand J Rheumatol (1988) 1.06
Anti-alpha-galactosyl antibodies and immune complexes in children with Henoch-Schönlein purpura or IgA nephropathy. Kidney Int (1987) 1.05
Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis. J Rheumatol (2000) 1.05
Anticipation in familial Crohn's disease. Gut (1998) 1.04
Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am J Gastroenterol (2002) 1.03
Differential production of cytokines and activation of NF-kappaB in HPV-transformed keratinocytes. Virology (2002) 1.02
Clinical and biological significance of interleukin-10 plasma levels in patients with septic shock. J Clin Immunol (1995) 1.02
Cytokine production from sputum cells after allergenic challenge in IgE-mediated asthma. Allergy (2002) 1.02
Effects of chondroitin sulfate and interleukin-1 beta on human articular chondrocytes cultivated in clusters. Osteoarthritis Cartilage (1998) 1.01
Innate lymphocyte and dendritic cell cross-talk: a key factor in the regulation of the immune response. Clin Exp Immunol (2008) 1.01
Increase in cytokine production (IL-1 beta, IL-6, TNF-alpha but not IFN-gamma, GM-CSF or LIF) by stimulated whole blood cells in postmenopausal osteoporosis. Maturitas (1997) 1.00
Cytochemistry of mouse mast cell reaction to polylysine. Histochemistry (1980) 1.00
Calcifying fibrous tumour of the gastric wall. Histopathology (2004) 1.00
Increased frequency of bronchial hyperresponsiveness in patients with inflammatory bowel disease. Allergy (1995) 0.98
Selective internal radiation therapy: distribution of radiation in the liver. Eur J Cancer Clin Oncol (1989) 0.98
Role of defective monocyte interleukin-10 release in tumor necrosis factor-alpha overproduction in alcoholics cirrhosis. Hepatology (1995) 0.97
Macrophage migration inhibitory factor (MIF) expression in human glioblastomas correlates with vascular endothelial growth factor (VEGF) expression. Neuropathol Appl Neurobiol (2002) 0.97
Profile of soluble cytokine receptors in Crohn's disease. Gut (2005) 0.97
Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). Eur J Gastroenterol Hepatol (1996) 0.96
The neuroendocrine thymus: coexistence of oxytocin and neurophysin in the human thymus. Science (1986) 0.96
Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. Clin Exp Rheumatol (2011) 0.95
Measurement of proteoglycans, elastase, collagenase and protein in synovial fluid in inflammatory and degenerative arthropathies. Clin Rheumatol (1985) 0.95
In vitro inhibition of tumour necrosis factor-alpha and interleukin-6 production by intravenous immunoglobulins. Br J Haematol (1995) 0.95
CARD4/NOD1 is not involved in inflammatory bowel disease. Gut (2003) 0.94
Correlation of T-helper secretory differentiation and types of antigen-presenting cells in squamous intraepithelial lesions of the uterine cervix. J Pathol (1998) 0.94
Inverse modulation of IL-10 and IL-12 in the blood of women with preneoplastic lesions of the uterine cervix. Clin Exp Immunol (1998) 0.94
Proviral genome of radiation leukemia virus: molecular cloning of biologically active proviral DNA and nucleotide sequence of its long terminal repeat. J Virol (1985) 0.93
Abnormal expression and structural modification of the insulin-like growth-factor-II gene in human colorectal tumors. Int J Cancer (1990) 0.93
Cytokine expression in squamous intraepithelial lesions of the uterine cervix: implications for the generation of local immunosuppression. Clin Exp Immunol (1998) 0.92
Healthcare consumption and direct costs of rheumatoid arthritis in Belgium. Clin Rheumatol (2005) 0.92
Acute pancreatitis attributed to the use of interferon alfa-2b. Gastroenterology (2000) 0.92
Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study. Ann Oncol (2011) 0.91
Tumor necrosis factor alpha levels in plasma and whole-blood culture in dengue-infected patients: relationship between virus detection and pre-existing specific antibodies. J Med Virol (1998) 0.91
Radioimmunoassay of cortisone in serum, urine, and saliva to assess the status of the cortisol-cortisone shuttle. Clin Chem (1997) 0.91
Effects of dexamethasone on the profile of cytokine secretion in human whole blood cell cultures. Regul Pept (1998) 0.91
Enhanced TNF alpha production by monocytic-like cells exposed to dengue virus antigens. Immunol Lett (1996) 0.90
Elevated anti-alpha-galactosyl antibody titres. A marker of progression in autoimmune thyroid disorders and in endocrine ophthalmopathy? Acta Endocrinol (Copenh) (1987) 0.90
Sleep in detoxified alcoholics: impairment of most standard sleep parameters and increased risk for sleep apnea, but not for myoclonias--a controlled study. J Stud Alcohol (1997) 0.90
EULAR report on the use of ultrasonography in painful knee osteoarthritis. Part 2: exploring decision rules for clinical utility. Ann Rheum Dis (2005) 0.90